Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
Read original at benzingaStocks · News reference
BeOne Medicines And Max Foundation Renew Partnership To Expand Access To BRUKINSA For The Treatment Of Chronic Lymphocytic Leukemia Through 2028
Partnership serves low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively.Building on a collaboration launched in 2023, the renewed partnership reflects the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 10:09 AM
- Checked
- Aug 18, 2026, 10:09 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with
Read original at benzingaBeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) Inhibitors
Companies also enter a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.Clinical collaboration will
Read original at benzinga